Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZLAB
CUSIPN/A
Phone86-21-6163-2588
Debt
Debt-to-Equity RatioN/A
Current Ratio19.12
Quick Ratio19.12
Price-To-Earnings
Trailing P/E Ratio-10.07
Forward P/E Ratio-15.59
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.77 per share
Price / Book4.74
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees52
Outstanding Shares50,560,000
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
What price target have analysts set for ZLAB?
3 brokerages have issued 1 year price objectives for Zai Lab's stock. Their forecasts range from $32.00 to $43.00. On average, they anticipate Zai Lab's stock price to reach $37.50 in the next twelve months. View Analyst Ratings for Zai Lab.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include Taro Pharmaceutical Industries (TARO), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), HUTCHISON CHINA/S (HCM), Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Horizon Pharma (HZNP), Blueprint Medicines (BPMC), Portola Pharmaceuticals (PTLA) and Ascendis Pharma A/S (ASND).
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Chairman and Chief Exec. Officer (Age 52)
- Mr. Xiaopeng Feng, VP of Fin. & Principal Accounting Officer (Age 45)
- Mr. Billy Cho, Chief Financial Officer
- Dr. Hui Wu, Chief Operating Officer (Age 50)
- Dr. Hongtao Lu, Exec. VP of Scientific Research
When did Zai Lab IPO?
(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
Has Zai Lab been receiving favorable news coverage?
Press coverage about ZLAB stock has been trending somewhat negative recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zai Lab earned a news sentiment score of -0.07 on Accern's scale. They also assigned news coverage about the company an impact score of 46.88 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Zai Lab's major shareholders?
Zai Lab's stock is owned by many different of institutional and retail investors. Top institutional investors include DU YING (17.42%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Millennium Management LLC (0.21%), Bamco Inc. NY (0.14%) and BlackRock Inc. (0.04%). View Institutional Ownership Trends for Zai Lab.
Which institutional investors are buying Zai Lab stock?
ZLAB stock was bought by a variety of institutional investors in the last quarter, including Bamco Inc. NY, Millennium Management LLC, BlackRock Inc. and Sumitomo Mitsui Trust Holdings Inc.. View Insider Buying and Selling for Zai Lab.
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $22.61.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $1.18 billion. The company earns $-50,380,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Zai Lab employs 52 workers across the globe.
How can I contact Zai Lab?
Zai Lab's mailing address is 1043 HALEI ROAD ZHANGJIANG HI-TECH PARK, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (ZLAB)
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
